Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Biogen is still looking at deals even after earmarking $5.6 billion to buy Apellis Pharmaceuticals earlier this month. “Most of what we’re going to be

AstraZeneca and the UK government are back in each other’s good graces. AstraZeneca on Wednesday said it is lifting its UK investment pause, with a

Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry’s vigorous spring shopping spree. The Italian pharma will

AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.